Preclinical BioPharma Proposals

Preclinical BioPharma Proposals

CHDI’s Outreach team is charged with seeking out advanced preclinical or clinical phase ligands for target validation studies in HD models and potential development as disease-modifying HD therapeutics. If you have a compound of interest and would like to collaborate with CHDI to evaluate it in an HD context we ask for a nonconfidential package that will be assigned to our science directors for review. CHDI’s Outreach team will determine whether there is interest and, if so, will work with you to develop a mutually agreeable plan. The type of a potential collaboration depends on the compound of interest and the nature of your request.

CHDI does not typically provide direct funding for preclinical evaluation of compounds. Most usually we will enter into a Compound Testing Agreement that allows us to test third-party molecules with our contract research organization (CRO) colleagues. We have a wide variety of validated assays available, some of them proprietary to CHDI, including generic ADMET assays, PK/PD endpoints, HD-specific cellular assays, and several disease progression measures in HD animal models. All studies conducted at CROs under a Compound Testing Agreement will be funded by CHDI, your company retains ownership of all intellectual property rights and data generated, and we typically do not ask for structures to be disclosed. You may opt to fund additional studies on your own on returned samples and animal tissues.

Our Outreach focuses on projects with relevance to HD that are at or near the “proof-of-concept” stage for in vivo animal testing. CHDI has internal drug discovery efforts that focus on earlier stage projects. We therefore do not provide funding for external drug screening or to optimize compounds at the hit-to-lead stage. CHDI can provide advice and pointers to a variety of resources, including HD animal model testing protocols available through our network of specialized CROs.

If you are interested in a potential collaboration, please provide the following information:

  1. What is the biological rationale for efficacy in HD?
  2. Without disclosing the structure, what is the compound’s biological profile?
  3. Provide a detailed nonconfidential information package about the molecules that will allow us to evaluate their potential for late-stage development. Ultimately, we need to understand how advanced the molecules are and the rationale for efficacy in HD.

Send your full contact information and nonconfidential information package to After evaluation we may set up an initial exploratory call between your team and our Outreach team. Please allow a few weeks for the internal review process.

Frequently Asked Questions

I have a clinical candidate for HD, how can I get involved with CHDI?

For all clinical questions, please email CHDI’s clinical group will liaise internally with the preclinical group to evaluate the scientific rationale and strength of the program before dedicating any significant time or resources to providing clinical advice.

I‘d like feedback on my HD research, can CHDI put me in touch with an expert?

If you are looking for preclinical advice, please send your specific questions and nonconfidential information package to and we will connect you to a CHDI science director with the relevant expertise.

I have a novel technology that I think will advance HD R&D. How can I collaborate with CHDI?

Submit a detailed nonconfidential information package to and we will direct your request.

Can CHDI help place a value on an asset?

CHDI does not provide valuations, investment guidance, or venture philanthropy